I have long lamented the fact that little research was likely to happen if there was no money to be made. Well, today I have been proven wrong. A university in the Netherlands is planning a double blind placebo controlled clinical trial of Niagen. The study is in patients with Parkinson's but really seeks to understand how Niagen may impact NAD+ and how that may be beneficial in slowing the progression of the disease. Enhancing NAD+ and Sirtuin activity is something that could help slow many neurological disorders including many forms of Ataxia. This would not be a cure, but rather an inexpensive and safe way to slow progression. In the study they propose to administer 1000 mg per day of Niagen to 200 patients with early Parkinson's. I should note that the title of the study says only "nicotinamide" but the summary explanation makes it clear the researchers are studying nicotinamide RIBOSIDE. They are not the same thing. Nicotinamide is known in short hand as NAM. Nicotinamide RIBOSIDE is known as NR. NAM and all other forms of vitamin B3 EXCEPT NIAGEN are Sirtuin INHIBTORS. NR or Niagen is the ONLY form of vitamin B3 that ENHANCES Sirtuins in the brain.
-
Anyways, like I said. Great day for Ataxia.
-
clinicaltrials.gov/ct2/show...
-
"Parkinson's disease (PD) is a major cause of death and disability and has a worldwide socioeconomic impact. It affects ~2% of the population above the age of 65 years and its prevalence increases dramatically as the population ages. The etiology and molecular pathogenesis underlying PD remain unknown. Recent evidence has implicated an impaired neuronal metabolism due to mitochondrial dysfunction, in particular NAD-deficiency is a key-event in the pathogenesis of PD. We propose that in order to correct this metabolic defect and treat PD, we need to boost neuronal NAD levels. This would improve mitochondrial function and could slow PD progression. Nicotinamide riboside is a precursor NAD vitamin. In this study we will investigate if nicotinamide riboside supplementation will correct NAD deficiency and thereby slow progression of PD symptoms. This study will recruit 200 patients with newly diagnosed PD and randomly assign them in an 1:1 ratio to either nicotinamide riboside or placebo administration for 52 weeks. During this trial the investigators will determine if nicotinamide riboside delays PD disease progression measured by clinical monitoring tools (MDS-UPDRS). Patients receiving nicotinamide riboside supplementation will receive a daily dose of 1000mg for the duration of the trial. This trial will also collect biological material from participants to see if nicotinamide riboside supplementation rectifies NAD deficiency and metabolism deficiencies."
-
-
Now if only we could convince the researchers to add mannitol or trehalose, we would REALLY have something
-
Cheers,
Joe in NY